A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

Study Identifier:
270-401
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
BioMarin Pharmaceutical
Collaborator:
N/A
Study Contact Information:
N/A
Recruiting

Study Details

Medical Condition
  • Hemophilia A
Study Drug
    Date
    Jan 2023 - Jan 2040
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Male
    Age: 18+ years years
    Requirements Information

    Protocol Summary

    This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

    Trial Locations

    Location
    Status
    Location
    Orthopedic Institute for Children, Orthopedic Hemophilia Treatment Center
    Los Angeles, California, United States, 90007
    Status
    N/A
    Location
    UC Davis Hemophilia Treatment Center
    Sacramento, California, United States, 95817
    Status
    N/A
    Location
    UCN Hemophilia and Thrombosis Center
    Shandon, California, United States, 27517
    Status
    N/A
    Location
    Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus
    Aurora, Colorado, United States, 80045
    Status
    N/A
    Location
    St Joseph's Children's Hospital, Center for Bleeding and Clotting Disorders
    Tampa, Florida, United States, 33614
    Status
    N/A
    Location
    University of Michigan, Pediatric Hematology and Oncology
    Ann Arbor, Michigan, United States, 48109-5718
    Status
    N/A